tef103 Antibody

What is tef103 antibody and what biological function does it target?

Tef103 antibody is an immunological reagent specifically designed to recognize and bind to the tef103 protein (also known as elongation factor 1-alpha-B/C or EF-1-alpha-B/C). This protein plays a crucial role in the process of protein biosynthesis by promoting GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein translation. The antibody serves as a valuable research tool for investigating translation mechanisms, protein synthesis regulation, and associated cellular pathways. Functionally, tef103 belongs to the TRAFAC class translation factor GTPase superfamily, specifically within the Classic translation factor GTPase family and EF-Tu/EF-1A subfamily. Within cells, the target protein is primarily localized in the cytoplasm where it participates in the protein synthesis machinery.

How does tef103 antibody differ from other translation factor antibodies?

Tef103 antibody differs from other translation factor antibodies through its specific epitope recognition patterns and binding characteristics. Unlike antibodies targeting related factors such as TEF3 (TEAD4), which functions as a transcriptional regulator binding to the M-CAT motif in muscle-specific gene promoters , tef103 antibody specifically targets the elongation factor involved in the translation mechanism itself.

The specificity is achieved through careful immunogen design and validation processes. For comparison, TEF3 antibodies typically target a nuclear transcription factor containing a TEA DNA-binding domain expressed primarily in skeletal muscle , while tef103 antibody targets a cytoplasmic translation elongation factor. This distinction is critical when designing experiments to investigate different aspects of gene expression regulation versus protein synthesis mechanisms.

What are the common synonyms and related nomenclature for tef103 antibody in scientific literature?

When reviewing scientific literature, researchers should be aware of the various nomenclature used to refer to tef103 antibody. The multiple designations include:

Database linkage: KEGG: spo:SPAC23A1.10

This diversity in nomenclature reflects the evolutionary conservation of the protein and its identification across different model systems. Understanding these alternative designations is essential when conducting comprehensive literature searches and interpreting research findings across different publications.

What are the primary research applications for tef103 antibody?

Tef103 antibody serves multiple research applications, primarily centered around investigating protein translation mechanisms. The most common applications include:

• Protein localization studies: Using immunofluorescence (IF) and immunohistochemistry (IHC) techniques to visualize the subcellular distribution of tef103 within tissues and cell types.

• Protein-protein interaction studies: Employing co-immunoprecipitation (Co-IP) to identify binding partners within the translation machinery.

• Expression analysis: Utilizing Western blotting (WB) to quantify expression levels across different tissues, developmental stages, or experimental conditions.

• Chromatin immunoprecipitation (ChIP): For investigating potential non-canonical roles in gene regulation.

• Functional inhibition studies: Using neutralizing antibodies to block function in cell-free translation systems.

The methodological approach varies based on the specific research question, with appropriate controls designed to account for potential cross-reactivity with related elongation factors.

What optimization strategies improve tef103 antibody performance in Western blotting experiments?

For optimal Western blotting results with tef103 antibody, researchers should implement several technical optimizations:

The storage conditions of the antibody significantly impact performance. For tef103 antibody, maintenance in 50% glycerol buffer with 0.01M PBS (pH 7.4) and 0.03% Proclin 300 as preservative at -20°C is recommended to preserve activity.

How can researchers validate the specificity of tef103 antibody for immunohistochemistry applications?

Validation of tef103 antibody specificity for immunohistochemistry requires a multi-pronged approach:

• Positive and negative tissue controls: Compare staining patterns in tissues known to express high levels of tef103 versus those with minimal expression.

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining if the antibody is truly specific.

• Knockout/knockdown validation: Compare staining patterns in wild-type versus tef103 knockout or knockdown samples.

• Cross-reactivity assessment: Test reactivity against closely related proteins, particularly other elongation factors.

• Antibody dilution series: A specific antibody will show a dose-dependent reduction in signal, while maintaining the same pattern.

For fixed tissue immunohistochemistry applications, an appropriate working dilution range would be 1:200-400, similar to ranges used for other translation factor antibodies . When conducting these validation experiments, it's critical to process all samples identically to ensure comparability of results.

How does post-translational modification of tef103 affect antibody recognition and experimental outcomes?

Post-translational modifications (PTMs) of tef103 can significantly impact antibody recognition, leading to potential misinterpretation of experimental results. Key considerations include:

• Phosphorylation effects: Tef103, like other elongation factors, can undergo regulatory phosphorylation, potentially masking or altering epitopes. This is particularly relevant when investigating stress responses or cell signaling pathways.

• Methylation and acetylation: These modifications can alter charge distribution and three-dimensional structure, affecting antibody binding efficiency.

• Experimental strategies:

  • Use phosphatase treatments as controls when phosphorylation status is uncertain

  • Employ antibodies recognizing different epitopes to capture the total protein population

  • Consider using modification-specific antibodies when investigating specific PTM states

• Western blotting interpretation: Multiple bands or shifts in molecular weight may indicate different modification states rather than non-specific binding or degradation products.

Researchers should consider the biological context of their experiments, as translational elongation factors are regulated differently under various cellular conditions including stress, differentiation, and disease states.

What are the technical challenges in using tef103 antibody for co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) studies with tef103 antibody present several technical challenges that require methodological adaptations:

• Transient interactions: As tef103 participates in dynamic translation complexes, cross-linking agents such as formaldehyde (0.1-0.5%) or DSP (dithiobis(succinimidyl propionate)) at 1-2 mM may be necessary to capture transient protein-protein interactions.

• Buffer composition optimization:

  • Include GDP/GTP analogs (0.1-0.5 mM) to stabilize specific conformational states

  • Adjust salt concentration (typically 100-150 mM NaCl) to maintain complex integrity while reducing non-specific binding

  • Include RNA-preserving components when investigating associations with tRNAs or ribosomes

• Antibody orientation: Using pre-bound antibody (direct IP) versus post-lysis addition (indirect IP) can significantly affect complex recovery.

• Controls to implement:

  • IgG isotype control from the same species

  • Reverse Co-IP with antibodies against suspected interaction partners

  • Input sample analysis (typically 5-10% of lysate used for IP)

  • Non-expressing or knockdown cell lines as negative controls

• Detection challenges: Western blotting after Co-IP may require specialized detection methods due to interference from heavy and light antibody chains, such as using TrueBlot® secondary antibodies or Light Chain Specific secondary antibodies.

How can researchers troubleshoot non-specific binding issues with tef103 antibody in immunofluorescence applications?

Non-specific binding is a common challenge when using tef103 antibody for immunofluorescence. Systematic troubleshooting should include:

• Fixation protocol optimization:

  • Compare paraformaldehyde (4%) versus methanol fixation

  • Evaluate permeabilization agents (0.1-0.5% Triton X-100 vs. 0.1% saponin)

  • Consider epitope retrieval methods if working with fixed tissues

• Blocking strategy refinement:

  • Test different blocking agents (5-10% normal serum from secondary antibody species)

  • Include 0.1-0.3% Triton X-100 in blocking buffer to reduce hydrophobic interactions

  • Add 1-5% BSA to reduce non-specific binding

• Antibody dilution optimization:

  • For immunofluorescence applications, a starting dilution range of 1:50-200 is recommended

  • Perform systematic titration series to determine optimal signal-to-noise ratio

• Washing protocol adjustment:

  • Increase number of washes (minimum 3x5 minutes)

  • Add 0.05-0.1% Tween-20 to wash buffer

  • Consider higher salt concentration (up to 500 mM NaCl) in one wash step

• Controls and validation:

  • Include a peptide competition control

  • Compare staining pattern with different antibodies targeting the same protein

  • Verify specificity using siRNA knockdown cells

The typical cytoplasmic localization pattern of tef103 should be carefully distinguished from non-specific background staining, which typically lacks specific subcellular compartmentalization.

How should researchers normalize and quantify tef103 expression data from Western blotting experiments?

Proper normalization and quantification of tef103 expression require rigorous analytical approaches:

• Selection of appropriate loading controls:

  • GAPDH or β-actin may be unsuitable in some experimental contexts as they can vary with cell conditions

  • Consider total protein normalization methods such as Ponceau S or REVERT Total Protein Stain

  • Use multiple housekeeping genes for verification in critical experiments

• Quantification methodology:

  • Employ digital image analysis software with linear dynamic range detection

  • Avoid saturated signals which invalidate quantitative comparisons

  • Calculate relative density using integrated density values rather than peak intensity

• Statistical considerations:

  • Perform technical triplicates (minimum) and biological replicates (3-5 independent experiments)

  • Use appropriate statistical tests based on data distribution (parametric vs. non-parametric)

  • Report standard deviation or standard error consistently

• Confounding factors to consider:

  • tef103 expression may vary with cell cycle phase

  • Stress conditions can alter expression and modification state

  • Sample preparation methods can affect extraction efficiency

A representative data analysis workflow might include background subtraction, normalization to loading control, calculation of fold change relative to control condition, and statistical comparison across replicates.

What criteria should be applied to determine cross-reactivity of tef103 antibody with related elongation factors?

Cross-reactivity assessment is crucial for accurate interpretation of tef103 antibody results:

• Sequence homology analysis:

  • Perform BLAST or alignment analysis of the immunizing peptide against related elongation factors

  • Identify regions of high similarity that might contribute to cross-reactivity

• Experimental validation methods:

  • Test antibody reactivity in cells with targeted knockdown of tef103

  • Compare staining patterns in tissues known to differentially express tef103 versus related factors

  • Use recombinant protein arrays containing related elongation factors

• Western blot signature analysis:

  • Compare observed band pattern with predicted molecular weights of related proteins

  • Evaluate multiple tissue types with known differential expression

• Mass spectrometry verification:

  • Perform immunoprecipitation followed by mass spectrometry to identify all proteins captured by the antibody

  • Quantify relative abundance of tef103 versus potentially cross-reactive proteins

Cross-reactivity considerations are particularly important when investigating organisms with multiple isoforms or paralogs of elongation factors, which might share significant epitope similarity due to evolutionary conservation of functional domains.

How can researchers distinguish between specific and non-specific binding patterns in immunohistochemical analyses using tef103 antibody?

Distinguishing specific from non-specific binding in immunohistochemistry requires systematic analytical criteria:

• Pattern analysis criteria:

  • Specific staining should match known subcellular localization (cytoplasmic for tef103)

  • Staining intensity should correlate with expected expression levels across different tissues

  • Cellular distribution should be consistent with biological function

• Gradient effect assessment:

  • Specific binding typically shows a titration effect with antibody dilution

  • Non-specific binding often persists even at high dilutions

• Control comparisons:

  • Secondary antibody-only controls should be completely negative

  • Isotype controls should show minimal background

  • Peptide competition should eliminate specific staining

• Technical artifact differentiation:

  • Edge effects and tissue folding often create non-specific staining

  • Necrotic areas typically show non-specific binding

  • Streptavidin-based detection systems may show endogenous biotin staining

• Quantitative assessment tools:

  • Use digital pathology software for objective intensity quantification

  • Apply automated scoring algorithms to minimize subjective interpretation

  • Implement dual-staining approaches to confirm cell type-specific expression

For immunohistochemical applications with tef103 antibody, a dilution range of 1:200-400 is typically appropriate , but this should be optimized for each tissue type and fixation method.

How can tef103 antibody be employed in multiplexed imaging systems to study translation dynamics?

Advanced multiplexed imaging with tef103 antibody enables comprehensive translation dynamics analysis:

• Multiplexed fluorescence imaging approaches:

  • Sequential imaging using fluorophore-conjugated antibodies against tef103 and other translation factors

  • Spectral unmixing techniques to differentiate overlapping signals

  • Multi-round imaging with antibody stripping and reprobing protocols

• Mass cytometry (CyTOF) applications:

  • Metal-tagged antibodies allow simultaneous detection of 40+ proteins

  • Enables correlation of tef103 with numerous pathway components and cell state markers

  • Particularly valuable for heterogeneous tissue samples

• In situ proximity ligation assay (PLA) implementation:

  • Detect interactions between tef103 and binding partners at single-molecule resolution

  • Quantify spatial relationships between translation factors in different cellular compartments

  • Measure dynamic changes in complex formation under various conditions

• Live-cell imaging considerations:

  • Antibody fragments (Fab, nanobodies) for intracellular tracking

  • Cell-permeable fluorescently labeled antibodies for real-time monitoring

  • Correlation with fluorescently tagged nascent peptides to track active translation sites

These advanced applications can reveal spatial regulation of translation, subcellular compartmentalization of translation machinery, and dynamic reorganization under stress conditions or disease states.

What are the considerations for using tef103 antibody in mass spectrometry-based proteomics workflows?

Integration of tef103 antibody into proteomics workflows requires specialized considerations:

• Immunoprecipitation-Mass Spectrometry (IP-MS) optimization:

  • Use cross-linking stabilization for transient interactions

  • Implement stringent washing to reduce background proteins

  • Consider on-bead digestion to minimize contaminants

• Antibody-based enrichment strategies:

  • Employ protein A/G-conjugated magnetic beads for efficient capture

  • Optimize elution conditions to maximize recovery while minimizing antibody contamination

  • Consider sequential IPs to identify specific subcomplexes

• Data analysis approaches:

  • Implement appropriate statistical methods for interactome analysis

  • Use label-free quantification or isobaric labeling for comparative studies

  • Apply interaction filtering algorithms to distinguish true interactors from background

• Validation strategies:

  • Confirm key interactions by reciprocal IP-MS

  • Verify novel interactions using orthogonal methods (Co-IP, PLA)

  • Compare interactome under different physiological conditions

• Technical considerations:

  • Evaluate antibody performance in IP efficiency tests before full-scale experiments

  • Consider epitope availability in native protein complexes

  • Test multiple antibody immobilization strategies to maximize capture efficiency

These approaches can reveal comprehensive tef103 interactomes, post-translational modification patterns, and dynamic changes in protein-protein interactions under different cellular conditions.

How do conformational states of tef103 affect epitope availability and antibody recognition in different experimental contexts?

Tef103 conformational dynamics present significant challenges for antibody-based detection:

• GTP/GDP-bound state considerations:

  • Elongation factors undergo substantial conformational changes during the GTPase cycle

  • Epitopes may be masked or exposed depending on nucleotide-binding status

  • Consider including GDP or non-hydrolyzable GTP analogs in buffers to stabilize specific conformations

• tRNA and ribosome association effects:

  • Binding of tef103 to aminoacyl-tRNA or ribosomes may alter antibody accessibility

  • Epitopes at interaction interfaces may be completely obscured in active complexes

  • Buffer conditions can influence complex stability and epitope availability

• Experimental strategies to address conformational heterogeneity:

  • Use multiple antibodies targeting different epitopes

  • Perform native versus denaturing comparisons to assess conformational recognition

  • Consider mild fixation conditions that preserve physiologically relevant conformations

• Analytical considerations:

  • Differential detection efficiency across conformational states may skew quantitative analyses

  • Complex formation may alter apparent molecular weight in size-based separations

  • Native electrophoresis can help resolve different conformational populations

Understanding these conformational considerations is particularly important when using tef103 antibody to investigate dynamic translation processes or when comparing results across different experimental systems with varying cofactor concentrations.